Macrolide treatment failure in streptococcal pharyngitis resulting in acute rheumatic fever

Pediatrics

Volumn 129, Issue 3, 2012, Pages

  Logan, Latania K ^a   McAuley, James B ^a   Shulman, Stanford T ^b  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Anti bacterial agents; Bacterial antigens; Bacterial drug resistance; Child; Drug resistance; Genotype; Macrolides; Pediatrics; Pharyngitis; Phenotype; Rheumatic fever; Streptococcal infections; Streptococcus pyogenes

Indexed keywords

ACETYLSALICYLIC ACID; ANTISTREPTOLYSIN; AZITHROMYCIN; C REACTIVE PROTEIN; CLINDAMYCIN; DIPHENHYDRAMINE; DNA ANTIBODY; ERYTHROMYCIN; IBUPROFEN; MACROLIDE; PENICILLIN V POTASSIUM; PREDNISONE;

ADOLESCENT; ANKLE PAIN; ANTIBIOTIC RESISTANCE; ANTIBODY BLOOD LEVEL; ANTIGEN DETECTION; ARTHRALGIA; ARTICLE; BACTERIAL STRAIN; CASE REPORT; CHILD; ECHOCARDIOGRAPHY; ERYTHEMA; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FEVER; HEMATOCRIT; HUMAN; JOINT SWELLING; LEUKOCYTE COUNT; MALE; MITRAL VALVE REGURGITATION; OTALGIA; PENICILLIN ALLERGY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RASH; RETINA MACULA VITELLIFORM DEGENERATION; RHEUMATIC FEVER; SCHOOL CHILD; SELF MEDICATION; SORE THROAT; STREPTOCOCCAL PHARYNGITIS; STREPTOCOCCUS GROUP A; STREPTOLYSIN TITER; SWELLING; THROAT CULTURE; THROMBOCYTE COUNT; TREATMENT RESPONSE; TRICUSPID VALVE REGURGITATION;

EID: 84857985608     PISSN: 00314005     EISSN: 10984275     Source Type: Journal    
DOI: 10.1542/peds.2011-1198     Document Type: Article

References (41)

1. Gerber MA. Streptococcus pyogenes (group A streptococcus). In: Long SS, Pickering LK, Prober CG, eds. Principles and Practice of Pediatric Infectious Diseases. 3rd (rev reprint) ed. Philadelphia, PA: Churchill Livingston Elsevier; 2009:700-711
2. Jaggi P, Shulman ST. Group A streptococcal infections. Pediatr Rev. 2006;27(3):99-105 (Pubitemid 46489399)
3. Gerber MA, Baltimore RS, Eaton CB, et al. Prevention of rheumatic fever and diagnosis and treatment of acute Streptococcal pharyngitis: a scientific statement from the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee of the Council on Cardiovascular Disease in the Young, the Interdisciplinary Council on Functional Genomics and Translational Biology, and the Interdisciplinary Council on Quality of Care and Outcomes Research: endorsed by the American Academy of Pediatrics. Circulation. 2009;119(11):1541-1551
4. Guidelines for the Diagnosis of Rheumatic Fever. Jones Criteria, 1992 update. Special Writing Group of the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease of the Council on Cardiovascular Disease in the Young of the American Heart Association. JAMA. 1992;268(15):2069-2073
5. Catanzaro FJ, Rammelkamp CH, Jr, Chamovitz R. Prevention of rheumatic fever by treatment of streptococcal infections. II. Factors responsible for failures. N Engl J Med. 1958;259(2):53-57
6. Dajani A, Taubert K, Ferrieri P, Peter G, Shulman S. Treatment of acute streptococcal pharyngitis and prevention of rheumatic fever: a statement for health professionals. Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease of the Council on Cardiovascular Disease in the Young, the American Heart Association. Pediatrics. 1995;96(4 pt 1):758-764
7. Freeman AF, Shulman ST. Macrolide resistance in group A Streptococcus. Pediatr Infect Dis J. 2002;21(12):1158-1160 (Pubitemid 35463035)
8. Woods CR. Macrolide-inducible resistance to clindamycin and the D-test. Pediatr Infect Dis J. 2009;28(12):1115-1118
9. Leclercq R. Mechanisms of resistance to macrolides and lincosamides: nature of the resistance elements and their clinical implications. Clin Infect Dis. 2002;34(4):482-492 (Pubitemid 34112269)
10. Sanchez ML, Flint KK, Jones RN. Occurrence of macrolide-lincosamide- streptogramin resistances among staphylococcal clinical isolates at a university medical center. Is false susceptibility to new macrolides and clindamycin a contemporary clinical and in vitro testing problem? Diagn Microbiol Infect Dis. 1993;16(3):205-213 (Pubitemid 23107303)
11. Beall B, Facklam R, Thompson T. Sequencing emm-specific PCR products for routine and accurate typing of group A streptococci. J Clin Microbiol. 1996;34(4):953-958 (Pubitemid 26091514)
12. Green M, Martin JM, Barbadora KA, Beall B, Wald ER. Reemergence of macrolide resistance in pharyngeal isolates of group a streptococci in southwestern Pennsylvania. Antimicrob Agents Chemother. 2004;48(2):473-476 (Pubitemid 38141704)
13. Martin JM, Green M, Barbadora KA, Wald ER. Erythromycin-resistant group A streptococci in schoolchildren in Pittsburgh. N Engl J Med. 2002;346(16):1200-1206 (Pubitemid 34984581)
14. Green MD, Beall B, Marcon MJ, et al. Multicentre surveillance of the prevalence and molecular epidemiology of macrolide resistance among pharyngeal isolates of group A streptococci in the USA. J Antimicrob Chemother. 2006;57(6):1240-1243 (Pubitemid 44644434)
15. Tanz RR, Rippe J, Kabat K, et al. National and local variations in group A streptococcal macrolide resistance in North America over 7 years. In: Proceedings from the Pediatric Academic Societies' Annual Meeting; May 6, 2008; Honolulu, HI. Abstract 6430.3
16. Tanz RR, Shulman ST, Shortridge VD, et al North American Streptococcal Pharyngitis Surveillance Group. Community-based surveillance in the united states of macrolide-resistant pediatric pharyngeal group A streptococci during 3 respiratory disease seasons. Clin Infect Dis. 2004;39(12):1794-1801 (Pubitemid 39657259)
17. Oliver MA, García-Delafuente C, Cano ME, Pérez- Hernández F, Martínez-Martínez L, Albertí S. Rapid decrease in the prevalence of macrolide-resistant group A streptococci due to the appearance of two epidemic clones in Cantabria (Spain). J Antimicrob Chemother. 2007;60(2):450-452 (Pubitemid 47243910)
18. Robinson DA, Sutcliffe JA, Tewodros W, Manoharan A, Bessen DE. Evolution and global dissemination of macrolide-resistant group A streptococci. Antimicrob Agents Chemother. 2006;50(9):2903-2911 (Pubitemid 44396391)
19. Silva-Costa C, Ramirez M, Melo-Cristino J. Identification of macrolide-resistant clones of Streptococcus pyogenes in Portugal. Clin Microbiol Infect. 2006;12(6):513-518 (Pubitemid 43740762)
20. Bergman M, Huikko S, Pihlajamäki M, et al Finnish Study Group for Antimicrobial Resistance (FiRe Network). Effect of macrolide consumption on erythromycin resistance in Streptococcus pyogenes in Finland in 1997-2001. Clin Infect Dis. 2004;38(9):1251-1256
21. Altamimi S, Khalil A, Khalaiwi KA, Milner R, Pusic MV, Al Othman MA. Short versus standard duration antibiotic therapy for acute streptococcal pharyngitis in children. Cochrane Database Syst Rev. 2009;(1):CD004872
22. Brook I. Azithromycin versus penicillin in acute group A streptococcal tonsillopharyngitis. Curr Infect Dis Rep. 2003;5(3):191-193
23. Takker U, Dzyublyk O, Busman T, Notario G. Comparison of 5 days of extended-release clarithromycin versus 10 days of penicillin V for the treatment of streptococcal pharyngitis/tonsillitis: results of a multicenter, double-blind, randomized study in adolescent and adult patients. Curr Med Res Opin. 2003;19(5):421-429 (Pubitemid 36994445)
24. Cohen R, Reinert P, De La Rocque F, et al. Comparison of two dosages of azithromycin for three days versus penicillin V for ten days in acute group A streptococcal tonsillopharyngitis. Pediatr Infect Dis J. 2002;21(4):297-303 (Pubitemid 34326867)
25. Jorgensen DM. Single-dose extended-release oral azithromycin vs. 3-day azithromycin for the treatment of group A beta-haemolytic streptococcal pharyngitis/tonsillitis in adults and adolescents: a double-blind, double-dummy study. Clin Microbiol Infect. 2009;15 (12):1103-1110
26. Lavergne V, Thibault L, Garceau R. Macrolide resistance in streptococcal pharyngitis. CMAJ. 2007;177(2):177
27. Sungur C. Acute rheumatic fever despite clarithromycin treatment of beta-hemolytic streptococcal tonsillitis. Ann Pharmacother. 1994;28(10):1197- 1198 (Pubitemid 24312264)
28. Ghirga G, Palazzi C, Ghirga P, Turchetti G, Turchetti A, Colaiacomo M. Inefficacy of a 3- day course of azithromycin in preventing acute rheumatic fever after group A streptococcal infection (scarlet fever) in an 8-year-old child. J Pediatr. 1999;134(1):123-124 (Pubitemid 29048694)
29. Rubinstein G, Amoroso AM, Bavdaz B, De Bunder S, Blazquez N, Gutkind GO. Low macrolide resistance in Streptococcus pyogenes in Southern Argentina. Int J Antimicrob Agents. 2005;25(5):450-452
30. Katz KC, McGeer AJ, Duncan CL, et al. Emergence of macrolide resistance in throat culture isolates of group a streptococci in Ontario, Canada, in 2001. Antimicrob Agents Chemother. 2003;47(7):2370-2372 (Pubitemid 36753606)
31. Liang Y, Shen X, Huang G, Wang C, Shen Y, Yang Y. Characteristics of Streptococcus pyogenes strains isolated from Chinese children with scarlet fever. Acta Paediatr. 2008;97(12):1681-1685
32. Koliou M, Ioannou Y, Efstratiou A, et al. Circulating serotypes and antimicrobial sensitivity of Streptococcus pyogenes isolates from children in Cyprus. Clin Microbiol Infect. 2007;13(6):645-647 (Pubitemid 46730673)
33. Bingen E, Bidet P, Mihaila-Amrouche L, et al. Emergence of macrolide-resistant Streptococcus pyogenes strains in French children. Antimicrob Agents Chemother. 2004;48(9):3559-3562 (Pubitemid 39129360)
34. Shackcloth J, Williams L, Farrell DJ. Streptococcus pneumoniae and Streptococcus pyogenes isolated from a paediatric population in Great Britain and Ireland: the in vitro activity of telithromcycin versus comparators. J Infect. 2004;48(3):229-235 (Pubitemid 38380381)
35. Malli E, Tatsidou E, Damani A, et al. Macrolide-resistant Streptococcus pyogenes in Central Greece: prevalence; mechanism and molecular identification. Int J Antimicrob Agents. 2010;35(6):614-615
36. Mazzariol A, Koncan R, Bahar G, Cornaglia G. Susceptibilities of Streptococcus pyogenes and Streptococcus pneumoniae to macrolides and telithromycin: data from an Italian multicenter study. J Chemother. 2007;19(5):500-507 (Pubitemid 350177960)
37. Koh EH, Kim S, Lee NY. Decrease of erythromycin resistance in group A streptococci by change of emm distribution. Jpn J Infect Dis. 2008;61(4):261-263
38. Zavadska D, Bērzina D, Drukalska L, Pugacova N, Miklasevics E, Gardovska D. Macrolide resistance in group A beta haemolytic Streptococcus isolated from outpatient children in Latvia. APMIS. 2010;118(5):366-370
39. Silva-Costa C, Pinto FR, Ramirez M, Melo-Cristino J; Portuguese Surveillance Group for the Study of Respiratory Pathogens. Decrease in macrolide resistance and clonal instability among Streptococcus pyogenes in Portugal. Clin Microbiol Infect. 2008;14(12):1152-1159
40. Pavlovic L, Grego E, Sipetic-Grujicic S. Prevalence of macrolide resistance in Streptococcus pyogenes collected in Serbia. Jpn J Infect Dis. 2010;63(4):275-276
41. Dundar D, Sayan M, Tamer GS. Macrolide and tetracycline resistance and emm type distribution of Streptococcus pyogenes isolates recovered from Turkish patients. Microb Drug Resist. 2010;16(4):279-284